National Lipid Association asks members to complete survey on PCSK9 inhibitors

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The National Lipid Association (NLA) is asking members to complete an online survey regarding challenges patients face in getting access to proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.

The NLA said prescribers and non-prescribers could complete the survey by Sept. 30.

The FDA has approved two PCSK9 inhibitors: alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) and evolocumab (Repatha, Amgen).

The injectable medications have been shown to lower low-density lipoprotein cholesterol, but trials are ongoing to determine if the drugs have an effect on cardiovascular mortality and morbidity.

Sales of the medications, which cost more than $14,000 per year, have fallen short of expectations since they were approved last summer.